Advaxis, Inc.'s Cancer Immunotherapy Featured On CBS News

PRINCETON, N.J., June 30, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced that ADXS-cHER2, its proprietary immunotherapy, was featured on CBS New York in a segment focused on encouraging data from a second study combining ADXS-cHER2 with radiation therapy to treat companion dogs with osteosarcoma (bone cancer). The reporters commented that treatment prolongs the lives of dogs with bone cancer and could one day help people with cancer. ADXS-cHER2 targets the Her2 receptor, which is overexpressed in certain solid-tumor cancers, including canine and human bone cancer and breast cancer. Advaxis intends to initiate a clinical development program with ADXS-cHER2 in pediatric osteosarcoma, based on previously reported canine data.

Help employers find you! Check out all the jobs and post your resume.